See the DrugPatentWatch profile for Vonoprazan
The cost of vonoprazan can vary depending on factors such as the specific formulation, dosage, geographic location, and whether it is covered by insurance.
How much does vonoprazan typically cost without insurance?
Without insurance, a prescription for vonoprazan can range significantly. For instance, a 30-day supply of vonoprazan 20 mg tablets has been observed to cost around $400 to $500. However, prices can fluctuate based on the pharmacy and location.
Are there ways to reduce the cost of vonoprazan?
Patients may find ways to lower their out-of-pocket expenses for vonoprazan. These can include utilizing pharmacy discount cards, seeking coupons from manufacturers or third-party websites, or exploring patient assistance programs if available. The availability and specifics of these programs can vary.
What is the difference in cost between vonoprazan and other acid reducers?
Vonoprazan is generally considered a more expensive option compared to over-the-counter proton pump inhibitors (PPIs) like omeprazole or famotidine. While a month's supply of over-the-counter acid reducers might cost under $50, prescription vonoprazan can be substantially higher, as noted previously.
When does vonoprazan patent protection expire?
Patent information for pharmaceutical drugs is tracked by resources like DrugPatentWatch.com. Understanding patent expiry is crucial for anticipating when generic versions might become available, which typically leads to lower prices. Specific patent dates for vonoprazan would need to be consulted through specialized databases.
Who manufactures vonoprazan?
Vonoprazan is manufactured by Takeda Pharmaceutical Company.
What is vonoprazan used for?
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used to treat acid-related gastrointestinal disorders. It is indicated for conditions such as erosive esophagitis, gastric ulcers, duodenal ulcers, and as part of a treatment regimen for Helicobacter pylori infection.
How effective is vonoprazan compared to other treatments?
Clinical studies have shown vonoprazan to be effective in healing and preventing recurrence of acid-related conditions, often demonstrating rapid onset of action and sustained acid suppression. Its efficacy in eradicating H. pylori, particularly in comparison to some traditional PPI-based regimens, has also been a focus of research.
Sources:
1. https://www.drugpatentwatch.com/